This week, 7 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

This is a strong week for Galapagos NV Sponsored ADR (GLPG). The company’s rating climbs to B from the previous week’s C. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of GLPG stock.

The rating of Emergent BioSolutions Inc. (EBS) moves up this week, rising from a B to a A. Emergent BioSolutions Inc. develops and produces immunobiotics, pharmaceutical products that assist the body’s immune system to prevent or treat disease. The company also gets A’s in sales growth and operating margin growth. For more information, get Portfolio Grader’s complete analysis of EBS stock.

FibroGen, Inc.’s (FGEN) ratings are looking better this week, moving up to a B from last week’s C. The company also gets A’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of FGEN stock.

Adamas Pharmaceuticals, Inc. (ADMS) is seeing ratings go up from a C last week to a B this week. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of ADMS stock.

Trevena, Inc. (TRVN) gets a higher grade this week, advancing from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of TRVN stock.

Recro Pharma, Inc. (REPH) earns a B this week, jumping up from last week’s grade of C. The company also gets A’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of REPH stock.

Immunomedics, Inc. (IMMU) improves from a C to a B rating this week. Immunomedics, Inc. develops, manufactures, and sells diagnostic imaging and therapeutic products. For more information, get Portfolio Grader’s complete analysis of IMMU stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.